PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.50
Current Ratio 0.5–0.75x Biotechnology median of 2.43. Guy Spier would worry about potential short-term pinch.
1.50
Quick Ratio 0.5–0.75x Biotechnology median of 2.11. Guy Spier would question if the company is at risk if bills come due rapidly.
1.48
Cash Ratio 1.25–1.5x Biotechnology median of 1.18. Mohnish Pabrai might see the market undervaluing high immediate liquidity.
-2327.49
Negative interest coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
-27.48
Negative short-term coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize cash flow quality and look for immediate refinancing solutions.